AbTherx Entered into a License Agreement with Gilead to Develop and Commercialize Novel Transgenic Mouse Technologies
- AbTherx gets the rights to Gilead's novel transgenic mouse technologies (developed by three of the AbTherx founders) & will be responsible to commercialize these technologies as Atlas Mice
- Under the terms of the agreement, Gilead gets a non-exclusive right for AbTherx-developed transgenic mouse technologies adding to Gilead's existing portfolio of Ab discovery technologies
- The agreement combines AbTherx’s experience in Ab discovery and developing transgenic mice with the addition of a platform to deliver the next generation of Ab therapies. AbTherx plans to further develop the technologies and partner with global pharmaceutical and biotechnology companies to deliver innovative therapies
Ref: Accesswire | Image: Gilead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.